HCW Biologics says IND filing remains on track for 1H 2027

HCW Biologics said FDA guidance from a recent Type B meeting supports preparation of its IND application for HCW11-018b in solid tumors. The company said manufacturing of cGMP material is underway and the filing remains targeted for the first half of 2027.